
- The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company shares traded at $60.96, up 1.65 percent in the after-hours trading session.
- Vaxart (NASDAQ:VXRT) announced positive top-line data from the first part of a planned two-part Phase 2 study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S. Vaxart shares traded as high as 2.26 percent, in a range of $2.91 to $3.17 on day volume of 5.23 million shares versus three months average volume of 2.57 million shares, closed regular trading session at $3.15. The company shares traded at $3.10, down 1.59 percent in the after-hours trading session.